BOEUF (Bonesupport Holding AB) ROCE % : 25.33% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Bonesupport Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bonesupport Holding AB's annualized ROCE % for the quarter that ended in Sep. 2024 was 25.33%.

Bonesupport Holding AB ROCE % Historical Data

The historical data trend for Bonesupport Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bonesupport Holding AB ROCE % Chart

Bonesupport Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-74.96

-37.88

-22.34

-21.10

4.51

Bonesupport Holding AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															14.17	-2.06	22.42	18.68	25.33

Bonesupport Holding AB ROCE % Calculation

Bonesupport Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1.839	/	( ( (35.828 - 8.691)	+	(67.152 - 12.679) )	/ 2 )
	=	1.839	/	( (27.137	+	54.473)	/ 2 )
	=	1.839	/	40.805
	=	4.51 %

Bonesupport Holding AB's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	16.02	/	( ( (71.767 - 10.855)	+	(76.122 - 10.553) )	/ 2 )
	=	16.02	/	( ( 60.912	+	65.569 )	/ 2 )
	=	16.02	/	63.2405
	=	25.33 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Bonesupport Holding AB (OTCPK:BOEUF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bonesupport Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Bonesupport Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bonesupport Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bonesupport Holding AB (OTCPK:BOEUF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BONEX:Sweden 0RQO:UK 2B4:Germany

Address

Scheelevagen 19, Lund, SWE, SE-223 70

Website

https://www.bonesupport.com

Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and sells injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and has the ability to release pharmaceuticals to promote healing. Its products focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: North America (NA) and Europe & Rest of the World (EUROW).